Idiopathic Pulmonary Fibrosis

Pharmacoeconomic Assessment of Nintedanib For The Treatment of Idiopathic Pulmonary Fibrosis In The Greek Healthcare System

Presented at ISPOR Europe. October 29 to November 2, 2016. Vienna, Austria.


Triaki G, Souliotis K, Bouros D, Papageogiou I, Diamantopoulos A, Rinciog C, Schmidt U

Publications in other disease areas

Atrial fibrillation

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke


Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom

Idiopathic pulmonary fibrosis

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review


The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis

Rheumatoid arthritis

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK


Venous thromboembolism

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective